Although the risk of transmission is low in dental settings, oral health professionals should be knowledgeable of any regulations requiring disclosure of an infectious disease.
Newer targeted therapies are being linked with medication-related osteonecrosis of the jaw, which underscores the need to stay abreast of its risk factors and etiologies.
On January 6, the U.S. Department of Health and Human Services (HHS) announced the U.S. Centers for Disease Control and Prevention (CDC) will provide more than $22 billion to states, localities and territories in response to the COVID-19…